Search

Your search keyword '"RODÉS CABAU, J"' showing total 865 results
Start Over Author "RODÉS CABAU, J"

Refine your results

more »

more »

more »

more »

more »
865 results on '"RODÉS CABAU, J"'

1. 2023 ESC Guidelines for the management of endocarditis

Author

Delgado, V, Ajmone Marsan, N, de Waha, S, Bonaros, N, Brida, M, Burri, H, Caselli, S, Doenst, T, Ederhy, S, Erba, P, Foldager, D, Fosbøl, E, Kovac, J, Mestres, C, Miller, O, Miro, J, Pazdernik, M, Pizzi, M, Quintana, E, Rasmussen, T, Ristić, A, Rodés-Cabau, J, Sionis, A, Zühlke, L, Borger, M, Delgado, Victoria, Ajmone Marsan, Nina, de Waha, Suzanne, Bonaros, Nikolaos, Brida, Margarita, Burri, Haran, Caselli, Stefano, Doenst, Torsten, Ederhy, Stephane, Erba, Paola Anna, Foldager, Dan, Fosbøl, Emil L, Kovac, Jan, Mestres, Carlos A, Miller, Owen I, Miro, Jose M, Pazdernik, Michal, Pizzi, Maria Nazarena, Quintana, Eduard, Rasmussen, Trine Bernholdt, Ristić, Arsen D, Rodés-Cabau, Josep, Sionis, Alessandro, Zühlke, Liesl Joanna, Borger, Michael A, Delgado, V, Ajmone Marsan, N, de Waha, S, Bonaros, N, Brida, M, Burri, H, Caselli, S, Doenst, T, Ederhy, S, Erba, P, Foldager, D, Fosbøl, E, Kovac, J, Mestres, C, Miller, O, Miro, J, Pazdernik, M, Pizzi, M, Quintana, E, Rasmussen, T, Ristić, A, Rodés-Cabau, J, Sionis, A, Zühlke, L, Borger, M, Delgado, Victoria, Ajmone Marsan, Nina, de Waha, Suzanne, Bonaros, Nikolaos, Brida, Margarita, Burri, Haran, Caselli, Stefano, Doenst, Torsten, Ederhy, Stephane, Erba, Paola Anna, Foldager, Dan, Fosbøl, Emil L, Kovac, Jan, Mestres, Carlos A, Miller, Owen I, Miro, Jose M, Pazdernik, Michal, Pizzi, Maria Nazarena, Quintana, Eduard, Rasmussen, Trine Bernholdt, Ristić, Arsen D, Rodés-Cabau, Josep, Sionis, Alessandro, Zühlke, Liesl Joanna, and Borger, Michael A

Published
2023

3. 14 Morbidly obese patients with symptomatic severe aortic stenosis, what is the optimal treatment strategy? A propensity score matched analysis of transcatheter versus surgical aortic valve replacement

Author

McInerney, A, primary, Rodés-Cabau, J, additional, Veiga, G, additional, Lopez-Otero, D, additional, Muñoz-Garcia, E, additional, Campelo, F, additional, Oteo, JF, additional, Carnero, M, additional, Tafur Soto, JD, additional, Amat-Santos, I, additional, Travieso, A, additional, Mohammadi, S, additional, Barbanti, M, additional, Cheema, AN, additional, Toggweiler, S, additional, Saia, F, additional, Dabrowski, M, additional, Serra, V, additional, Alfonso, F, additional, Barbosa, H, additional, Regueiro, A, additional, Alperi, A, additional, Ongay, AG, additional, Martinez Cereijo, JM, additional, Muñoz-Garcia, AJ, additional, Matta, A, additional, Arellano-Serrano, C, additional, Barrero, A, additional, Tirado-Conte, G, additional, Gonzalo, N, additional, Sanmartin, XC, additional, de la Torre Hernández, JM, additional, Kalavrouziotis, D, additional, Maroto, L, additional, Forteza-Gil, A, additional, Cobiella, J, additional, Escaned, J, additional, and Nombela-Franco, L, additional

Published
2022
Full Text
View/download PDF

4. Effect of Glomerular Filtration Rates on Outcomes Following Percutaneous Left Atrial Appendage Closure

Author

Faroux L., Cruz-González I., Arzamendi D., Freixa X., Nombela-Franco L., Peral V., Caneiro-Queija B., Mangieri A., Trejo-Velasco B., Asmarats L., Regueiro A., McInerney A., Mas-Lladó C., Estevez-Loureiro R., Laricchia A., O'Hara G., and Rodés-Cabau J.

Subjects
glomerulus filtration rate, estimated glomerular filtration rate, very elderly, Embolism, clinical outcome, complication, Comorbidity, left atrial appendage closure, anticoagulant agent, Article, male, Kidney Failu, heart atrium appendage, Atrial Fibrillation, severity of illness index, Humans, Atrial Appendage, postoperative complication, human, Cardiac Surgical Procedures, thrombosis, Ischemic Stroke, Aged, 80 and over, hemodialysis, Anticoagulants, antithrombocytic agent, postoperative hemorrhage, chronic kidney failure, bleeding, major clinical study, interventional cardiovascular procedure, brain ischemia, heart surgery, Cardiac Tamponade, aged, multicenter study, female, priority journal, Ischemic Attack, Transient, transient ischemic attack, mortality risk, disease severity, cerebrovascular accident, heart tamponade, prospective study, Glomerular Filtration Rate
Abstract

Scarce data support the prescription of oral anticoagulation in patients with concomitant advanced chronic kidney disease (CKD) and atrial fibrillation, and left atrial appendage closure (LAAC) may provide a favorable risk-benefit ratio in this population. However, outcomes of LAAC in CKD patients are unknown. We aimed to investigate the impact of moderate-to-severe CKD on clinical outcomes following percutaneous LAAC. This was a multicenter study including 1094 patients who underwent LAAC. Moderate-to-severe CKD was defined as an eGFR

Published
2021

5. Transcatheter Replacement of Transcatheter Versus Surgically Implanted Aortic Valve Bioprostheses

Author

Landes, U, Sathananthan, J, Witberg, G, de Backer, O, Sondergaard, L, Abdel-Wahab, M, Holzhey, D, Kim, WK, Hamm, C, Buzzatti, N, Montorfano, M, Ludwig, S, Conradi, L, Seiffert, M, Guerrero, M, El Sabbagh, A, Rodés-Cabau, J, Guimaraes, L, Codner, P, Okuno, T, Pilgrim, T, Fiorina, C, Colombo, A, Mangieri, A, Eltchaninoff, H, Nombela-Franco, L, van Wiechen, Maarten, van Mieghem, Nicolas, Tchétché, D, Schoels, WH, Kullmer, M, Tamburino, C, Sinning, JM, Al-Kassou, B, Perlman, GY, Danenberg, H, Ielasi, A, Fraccaro, C, Tarantini, G, De Marco, F, Redwood, SR, Lisko, JC, Babaliaros, VC, Laine, M, Nerla, R, Castriota, F, Finkelstein, A, Loewenstein, I, Eitan, A, Jaffe, R, Ruile, P, Neumann, FJ, Piazza, N, Alosaimi, H, Sievert, H, Sievert, K, Russo, M, Andreas, M, Bunc, M, Latib, A, Godfrey, R, Hildick-Smith, D, Chuang, MYA, Blanke, P, Leipsic, J, Wood, DA, Nazif, T M, Kodali, S, Barbanti, M, Kornowski, R, Leon, MB, Webb, JG, Landes, U, Sathananthan, J, Witberg, G, de Backer, O, Sondergaard, L, Abdel-Wahab, M, Holzhey, D, Kim, WK, Hamm, C, Buzzatti, N, Montorfano, M, Ludwig, S, Conradi, L, Seiffert, M, Guerrero, M, El Sabbagh, A, Rodés-Cabau, J, Guimaraes, L, Codner, P, Okuno, T, Pilgrim, T, Fiorina, C, Colombo, A, Mangieri, A, Eltchaninoff, H, Nombela-Franco, L, van Wiechen, Maarten, van Mieghem, Nicolas, Tchétché, D, Schoels, WH, Kullmer, M, Tamburino, C, Sinning, JM, Al-Kassou, B, Perlman, GY, Danenberg, H, Ielasi, A, Fraccaro, C, Tarantini, G, De Marco, F, Redwood, SR, Lisko, JC, Babaliaros, VC, Laine, M, Nerla, R, Castriota, F, Finkelstein, A, Loewenstein, I, Eitan, A, Jaffe, R, Ruile, P, Neumann, FJ, Piazza, N, Alosaimi, H, Sievert, H, Sievert, K, Russo, M, Andreas, M, Bunc, M, Latib, A, Godfrey, R, Hildick-Smith, D, Chuang, MYA, Blanke, P, Leipsic, J, Wood, DA, Nazif, T M, Kodali, S, Barbanti, M, Kornowski, R, Leon, MB, and Webb, JG

Abstract

Background: Surgical aortic valve replacement and transcatheter aortic valve replacement (TAVR) are now both used to treat aortic stenosis in patients in whom life expectancy may exceed valve durability. The choice of initial bioprosthesis should therefore consider the relative safety and efficacy of potential subsequent interventions. Objectives: The aim of this study was to compare TAVR in failed transcatheter aortic valves (TAVs) versus surgical aortic valves (SAVs). Methods: Data were collected on 434 TAV-in-TAV and 624 TAV-in-SAV consecutive procedures performed at centers participating in the Redo-TAVR international registry. Propensity score matching was applied, and 330 matched (165:165) patients were analyzed. Principal endpoints were procedural success, procedural safety, and mortality at 30 days and 1 year. Results: For TAV-in-TAV versus TAV-in-SAV, procedural success was observed in 120 (72.7%) versus 103 (62.4%) patients (p = 0.045), driven by a numerically lower frequency of residual high valve gradient (p = 0.095), ectopic valve deployment (p = 0.081), coronary obstruction (p = 0.091), and conversion to open heart surgery (p = 0.082). Procedural safety was achieved in 116 (70.3%) versus 119 (72.1%) patients (p = 0.715). Mortality at 30 days was 5 (3%) after TAV-in-TAV and 7 (4.4%) after TAV-in-SAV (p = 0.570). At 1 year, mortality was 12 (11.9%) and 10 (10.2%), respectively (p = 0.633). Aortic valve area was larger (1.55 ± 0.5 cm2 vs. 1.37 ± 0.5 cm2; p = 0.040), and the mean residual gradient was lower (12.6 ± 5.2 mm Hg vs. 14.9 ± 5.2 mm Hg; p = 0.011) after TAV-in-TAV. The rate of moderate or greater residual aortic regurgitation was similar, but mild aortic regurgitation was more frequent after TAV-in-TAV (p = 0.003). Conclusions: In propensity score–matched cohorts of TAV-in-TAV versus TAV-in-SAV patients, TAV-in-TAV was associated with higher procedural success and similar procedural safety or mortality.

Published
2021

9. Management of Conduction Disturbances Associated With Transcatheter Aortic Valve Replacement:JACC Scientific Expert Panel

Author

Rodés-Cabau, J., Ellenbogen, Kenneth A., Krahn, Andrew D., Latib, A., Mack, Michael, Mittal, Suneet, Muntané-Carol, Guillem, Nazif, Tamim M., Sondergaard, Lars, Urena, Marina, Windecker, Stephan, Philippon, François, Rodés-Cabau, J., Ellenbogen, Kenneth A., Krahn, Andrew D., Latib, A., Mack, Michael, Mittal, Suneet, Muntané-Carol, Guillem, Nazif, Tamim M., Sondergaard, Lars, Urena, Marina, Windecker, Stephan, and Philippon, François

Abstract

Despite major improvements in transcatheter aortic valve replacement (TAVR) periprocedural complications in recent years, the occurrence of conduction disturbances has not decreased over time and remains the most frequent complication of the procedure. Additionally, there has been an important lack of consensus on the management of these complications, which has indeed translated into a high degree of uncertainty regarding the most appropriate treatment of a large proportion of such patients along with major differences between centers and studies in pacemaker rates post-TAVR. There is therefore an urgent need for a uniform strategy regarding the management of conduction disturbances after TAVR. The present expert consensus scientific panel document has been formulated by a multidisciplinary group of interventional cardiologists, electrophysiologists, and cardiac surgeons as an initial attempt to provide a guide for the management of conduction disturbances after TAVR based on the best available data and group expertise.

Published
2019

14. Evaluation of current practices in transcatheter aortic valve implantation: The WRITTEN (WoRldwIde TAVI ExperieNce) survey

Author

Cerrato, E. (Enrico), Nombela-Franco, L. (Luis), Nazif, T.M. (Tamim M.), Eltchaninoff, H. (Hélène), Søndergaard, L. (Lars), Ribeiro, H.B. (Henrique), Barbanti, M. (Marco), Nietlispach, F. (Fabian), Jaegere, P.P.T. (Peter) de, Agostoni, P. (Pierfrancesco), Trillo, R. (Ramiro), Jiménez-Quevedo, P., D'Ascenzo, F. (Fabrizio), Wendler, O. (Olaf), Maluenda, G. (Gabriel), Chen, M. (Mao), Tamburino, C. (Corrado), MacAya, C. (Carlos), Leon, M.B. (Martin), Rodés-Cabau, J. (Josep), Cerrato, E. (Enrico), Nombela-Franco, L. (Luis), Nazif, T.M. (Tamim M.), Eltchaninoff, H. (Hélène), Søndergaard, L. (Lars), Ribeiro, H.B. (Henrique), Barbanti, M. (Marco), Nietlispach, F. (Fabian), Jaegere, P.P.T. (Peter) de, Agostoni, P. (Pierfrancesco), Trillo, R. (Ramiro), Jiménez-Quevedo, P., D'Ascenzo, F. (Fabrizio), Wendler, O. (Olaf), Maluenda, G. (Gabriel), Chen, M. (Mao), Tamburino, C. (Corrado), MacAya, C. (Carlos), Leon, M.B. (Martin), and Rodés-Cabau, J. (Josep)

Abstract

Background Transcatheter aortic valve implantation (TAVI) has been adopted worldwide as the standard treatment for severe aortic stenosis in symptomatic patients at prohibitive or high surgical risk, but there are still several areas where consensus and evidence are lacking. The purpose was to obtain a global view of current practice related to TAVI with the potential to identify the main areas of consensus and divergence between centers. Methods An online questionnaire was distributed in centers performing TAVI including a total of 59 questions concerning pre-procedural evaluation, procedural practices and post-procedural management. Results The survey was completed by 250 centers (with a cumulative experience of nearly 70,000 TAVI) from 38 different countries. Heart team meetings and surgical risk scores were routinely performed in most (> 95%) centers, but frailty (44%) and quality of life (28%) assessments were less frequently performed. General anesthesia remained the most frequent type of anesthesia (60% of centers), and significant variability was detected in the examinations for residual aortic regurgitation assessment during the procedure and in post-procedural ECG monitoring and temporary pacemaker implementation (from none to ≥ 72 h post-TAVI). Dual antiplatelet therapy duration post-TAVI was highly variable (1, 3, and ≥ 6 months in 14%, 41% and 32% of centers, respectively) and lack of consensus in antithrombotic regimen was observed in patients with atrial fibrillation requiring anticoagulation therapy (anticoagulation alone, anticoagulation + aspirin, anticoagulation + clopidogrel, and triple therapy in 28%, 37%, 26% and 4% of centers, respectively). Conclusions The WRITTEN survey provided extensive data on current TAVI-related practice and identified important differences between centers in key aspects of pre-, intra-, and post-operative management. This highlights the urgent need for further studies and evidence-based data to guide multiple aspects o

Published
2017
Full Text
View/download PDF

19. TRANSCATHETER AORTIC VALVE IMPLANTATION IN QUÉBEC: 4 YEARS OF COMPREHENSIVE EVALUATION AND RELATION TO QUALITY INDICATORS

Author

Lambert, L., primary, Azzi, L., additional, Désy, F., additional, Potter, B., additional, Racine, N., additional, Beauchemin, J., additional, Noiseux, N., additional, Asgar, A., additional, Daneault, B., additional, de Varennes, B., additional, Dumont, E., additional, Ibrahim, R., additional, Lamarche, Y., additional, Martucci, G., additional, Palisaitis, D., additional, Piazza, N., additional, Rodés-Cabau, J., additional, Afilalo, J., additional, Carrier, M., additional, de Guise, M., additional, and Bogaty, P., additional

Published
2017
Full Text
View/download PDF

20. IMPACT OF PRE-EXISTENT PROSTHESIS-PATIENT MISMATCH ON HEMODYNAMIC OUTCOME FOLLOWING AORTIC VALVE-IN-VALVE FOR THE TREATMENT OF FAILED SURGICAL BIOPROSTHESES

Author

Zenses, A., primary, Dahou, A., additional, Salaun, E., additional, Rodés-Cabau, J., additional, De Larochellière, R., additional, Paradis, J., additional, Doyle, D., additional, Mohammadi, S., additional, Dumont, E., additional, Chamandi, C., additional, Rodriguez-Gabella, T., additional, Rieu, R., additional, Clavel, M., additional, and Pibarot, P., additional

Published
2017
Full Text
View/download PDF

21. Revisiting Sex Equality with Transcatheter Aortic Valve Replacement Outcomes A Collaborative, Patient-Level Meta-Analysis of 11,310 Patients

Author

O'Connor, Sa, Morice, Mc, Gilard, M, Leon, Mb, Webb, Jg, Dvir, D, Rodés Cabau, J, Tamburino, Corrado, Capodanno, DAVIDE FRANCESCO MARIA, D'Ascenzo, F, Garot, P, Chevalier, B, Mikhail, Gw, and Ludman, Pf

Subjects
Male, aortic stenosis, gender, transcatheter aortic valve implantation, transcatheter aortic valve replacement, Aged, Aged, 80 and over, Aortic Valve, Female, Humans, Incidence, Outcome Assessment (Health Care), Patient Selection, Postoperative Complications, Risk Factors, Severity of Illness Index, Sex Factors, Survival Analysis, Aortic Valve Stenosis, Heart Valve Prosthesis, Hemorrhage, Stroke, Transcatheter Aortic Valve Replacement, Cardiology and Cardiovascular Medicine, Medicine (all), 80 and over
Abstract

BackgroundThere has been conflicting clinical evidence as to the influence of female sex on outcomes after transcatheter aortic valve replacement.ObjectivesThe aim of this study was to evaluate the impact of sex on early and late mortality and safety end points after transcatheter aortic valve replacement using a collaborative meta-analysis of patient-level data.MethodsFrom the MEDLINE, Embase, and the Cochrane Library databases, data were obtained from 5 studies, and a database containing individual patient-level time-to-event data was generated from the registry of each selected study. The primary outcome of interest was all-cause mortality. The safety end point was the combined 30-day safety end points of major vascular complications, bleeding events, and stroke, as defined by the Valve Academic Research Consortium when available.ResultsFive studies and their ongoing registry data, comprising 11,310 patients, were included. Women constituted 48.6% of the cohort and had fewer comorbidities than men. Women had a higher rate of major vascular complications (6.3% vs. 3.4%; p < 0.001), major bleeding events (10.5% vs. 8.5%; p = 0.003), and stroke (4.4% vs. 3.6%; p = 0.029) but a lower rate of significant aortic incompetence (grade ≥2; 19.4% vs. 24.5%; p < 0.001). There were no differences in procedural and 30-day mortality between women and men (2.6 % vs. 2.2% [p = 0.24] and 6.5% vs. 6.5% [p = 0.93], respectively), but female sex was independently associated with improved survival at median follow-up of 387 days (interquartile range: 192 to 730 days) from the index procedure (adjusted hazard ratio: 0.79; 95% confidence interval: 0.73 to 0.86; p = 0.001).ConclusionsAlthough women experience more bleeding events, as well as vascular and stroke complications, female sex is an independent predictor of late survival after transcatheter aortic valve replacement. This should be taken into account during patient selection for this procedure.

Published
2015

26. Clinical impact of aortic regurgitation after transcatheter aortic valve replacement: insights into the degree and acuteness of presentation

Author

Jerez Valero, M, Urena, M, Webb, Jg, Tamburino, Corrado, Munoz Garcia AJ, Cheema, A, Dager, Ae, Serra, V, Amat Santos IJ, Barbanti, M, Immè, S, Alonso Briales JH, Al Lawati, H, Benitez, Lm, Cucalon, Am, Garcia del Blanco, B, Revilla, A, Dumont, E, Barbosa Ribeiro, H, Nombela Franco, L, Bergeron, S, Pibarot, P, and Rodés Cabau, J.

Published
2014

28. AORTIC STENOSIS SEVERITY IN LOW-FLOW LOW-GRADIENT AORTIC STENOSIS: COMPARISON BETWEEN DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND AORTIC VALVE CALCIFICATION MEASURED BY COMPUTED TOMOGRAPHY -THE TOPAS STUDY-

Author

Dahou, A., primary, Clavel, M., additional, Larose, É., additional, Capoulade, R., additional, Bartko, P.E., additional, Ribeiro, H.B., additional, Tastet, L., additional, Bergler-Klein, J., additional, Mundigler, G., additional, Burwash, I.G., additional, Dumesnil, J.G., additional, Senechal, M., additional, O'Connor, K., additional, Baumgartner, H., additional, Rodés-Cabau, J., additional, and Pibarot, P., additional

Published
2015
Full Text
View/download PDF

30. USE AND OUTCOMES OF TRANSCATHETER AORTIC VALVE IMPLANTATION: RESULTS OF A QUÉBEC-WIDE FIELD EVALUATION

Author

Lambert, L.J., primary, Sas, G., additional, Azzi, L., additional, Daneault, B., additional, Généreux, P., additional, Noiseux, N., additional, Lamarche, Y., additional, Martucci, G., additional, Ibrahim, R., additional, Benoit, D., additional, Dumont, É., additional, Rodés-Cabau, J., additional, Carrier, M., additional, Morin, J.E., additional, and Bogaty, P., additional

Published
2015
Full Text
View/download PDF

31. WHAT ARE THE BEST INDICATORS OF THE PERFORMANCE OF TRANSCATHETER AORTIC VALVE IMPLANTATION? MEASURES OF QUALITY IN QUÉBEC COMPARED WITH INTERNATIONAL REGISTRIES

Author

Lambert, L.J., primary, Sas, G., additional, Azzi, L., additional, Carrier, M., additional, Daneault, B., additional, Dumont, É., additional, Généreux, P., additional, Ibrahim, R., additional, Lamarche, Y., additional, Martucci, G., additional, Noiseux, N., additional, Rodés-Cabau, J., additional, de Varennes, B., additional, Morin, J.E., additional, and Bogaty, P., additional

Published
2015
Full Text
View/download PDF

32. Occurrence,,fate and consequences of ventricular conduction abnormalities after transcatheter aortic valve implantation

Author

Houthuizen, P. (Patrick), Boon, R.M.A. (Robert) van der, Urena, M. (Marina), Mieghem, N.M. (Nicolas) van, Brueren, G.B.R. (Guus B.), Poels, T.T. (Thomas), Garsse, L. (Leen) van, Rodés-Cabau, J. (Josep), Prinzen, F.W. (Frits), Jaegere, P.P.T. (Peter) de, Houthuizen, P. (Patrick), Boon, R.M.A. (Robert) van der, Urena, M. (Marina), Mieghem, N.M. (Nicolas) van, Brueren, G.B.R. (Guus B.), Poels, T.T. (Thomas), Garsse, L. (Leen) van, Rodés-Cabau, J. (Josep), Prinzen, F.W. (Frits), and Jaegere, P.P.T. (Peter) de

Abstract

Aims: Transcatheter aortic valve implantation (TAVI) is frequently complicated by new left bundle branch block (LBBB). We investigated the development and persistence of LBBB during follow-up and its clinical consequences. Methods and results: ECGs at baseline, within 24 hours, before discharge and at 12 months after TAVI were assessed in 476 patients without pre-existing LBBB and/or pacemaker before or after TAVI. TAVI-induced new LBBB was categorised based on the timing of the occurrence (within 24 hours [acute], after 24 hours but before discharge [subacute], and after discharge [late]), in addition to persistence (transient or persistent). A total of 175 patients (36.8%) developed new LBBB of which 85.7% occurred within 24 hours after TAVI, 12.0% before and 2.3% after hospital discharge, and was persistent in 111 patients (63.4%). Implantation of the Medtronic CoreValve System (MCS) more frequently led to new LBBB than the balloon-expandable Edwards SAPIEN valve (ES) (53.8% versus 21.7%) with less recovery during follow-up (39.0% versus 9.5%). Late new LBBB was only seen in four patients (0.8%). During a median follow-up of 915 (578-1,234) days, persistent LBBB was associated with a significant increase in mortality as compared to no LBBB and temporary LBBB combined (hazard ratio 1.49, 95% confidence interval, 1.10-2.03; p=0.01). Conclusions: TAVI-induced new LBBB occurs in almost 40% of patients, almost all before hospital discharge. It occurs three times more frequently after MCS than after ES valve implantation and has a twofold lower tendency to resolve during follow-up. Persistent LBBB is associated with a higher mortality.

Published
2014
Full Text
View/download PDF

35. MODERATE/SEVERE DIASTOLIC DYSFUNCTION IS ASSOCIATED WITH WORSE OUTCOME IN PATIENTS WITH LOW-FLOW, LOW-GRADIENT AORTIC STENOSIS AND LOW EJECTION FRACTION -Results OF THE TOPAS STUDY

Author

Dahou, A., primary, Clavel, M., additional, Bartko, P., additional, Capoulade, R., additional, Mundigler, G., additional, Bergler-klein, J., additional, Burwash, I.G., additional, Ribeiro, H.B., additional, Dumesnil, J.G., additional, Senechal, M., additional, O'Connor, K., additional, Baumgartner, H., additional, Rodés-Cabau, J., additional, and Pibarot, P., additional

Published
2014
Full Text
View/download PDF

36. USE AND OUTCOMES OF TRANSCATHETER AORTIC VALVE IMPLANTATION: Results OF A QUÉBEC-WIDE FIELD EVALUATION AND COMPARISON WITH THE TVT REGISTRY

Author

Lambert, L.J., primary, Sas, G., additional, Dragieva, N., additional, Daneault, B., additional, Généreux, P., additional, Noiseux, N., additional, Lamarche, Y., additional, Martucci, G., additional, Ibrahim, R., additional, de Varennes, B., additional, Dumont, E., additional, Rodés-Cabau, J., additional, Carrier, M., additional, Spaziano, M., additional, Morin, J.E., additional, and Bogaty, P., additional

Published
2014
Full Text
View/download PDF

37. Prognostic value of exercise capacity as evaluated by the 6-minute walk test in patients undergoing transcatheter aortic valve implantation.

Author

Mok, Michael, Nombela-Franco, L, Urena, M, Delarochellière, R, Doyle, D, Ribeiro, HB, Côté, M, Pibarot, P, Delarochellière, H, Laflamme, L, Poirier, P, Dumont, E, Rodés-Cabau, J, Mok, Michael, Nombela-Franco, L, Urena, M, Delarochellière, R, Doyle, D, Ribeiro, HB, Côté, M, Pibarot, P, Delarochellière, H, Laflamme, L, Poirier, P, Dumont, E, and Rodés-Cabau, J

Published
2013

38. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document

Author

Kappetein, A.P. (Arie Pieter), Head, S.J. (Stuart), Généreux, P. (Philippe), Piazza, N. (Nicolo), Mieghem, N.M. (Nicolas) van, Blackstone, E.H. (Eugene), Brott, T.G. (Thomas), Cohen, D.J. (David J.), Cutlip, D.E. (Donald), Es, G.A. (Gerrit Anne) van, Hahn, R.T. (Rebecca), Kirtane, A.J. (Ajay), Krucoff, M. (Mitchell), Kodali, S. (Susheel), Mack, M.J. (Michael), Mehran, R. (Roxana), Rodés-Cabau, J. (Josep), Vranckx, P. (Pascal), Webb, J.G. (John), Windecker, S.W. (Stephan), Serruys, P.W.J.C. (Patrick), Leon, M.B. (Martin), Kappetein, A.P. (Arie Pieter), Head, S.J. (Stuart), Généreux, P. (Philippe), Piazza, N. (Nicolo), Mieghem, N.M. (Nicolas) van, Blackstone, E.H. (Eugene), Brott, T.G. (Thomas), Cohen, D.J. (David J.), Cutlip, D.E. (Donald), Es, G.A. (Gerrit Anne) van, Hahn, R.T. (Rebecca), Kirtane, A.J. (Ajay), Krucoff, M. (Mitchell), Kodali, S. (Susheel), Mack, M.J. (Michael), Mehran, R. (Roxana), Rodés-Cabau, J. (Josep), Vranckx, P. (Pascal), Webb, J.G. (John), Windecker, S.W. (Stephan), Serruys, P.W.J.C. (Patrick), and Leon, M.B. (Martin)

Abstract

Objectives: The aim of the current Valvular Academic Research Consortium (VARC)-2 initiative was to revisit the selection and definitions of transcatheter aortic valve implantation (TAVI)- clinical endpoints to make them more suitable to the present and future needs of clinical trials. In addition, this document is intended to expand understanding of patient risk stratification and case selection. Background: A recent study confirmed that VARC definitions have already been incorporated into clinical and research practice and represent a new standard for consistency in reporting clinical outcomes of patients with symptomatic severe aortic stenosis (AS) undergoing TAVI. However, as the clinical experience with this technology has matured and expanded, certain definitions have become unsuitable or ambiguous. Methods and results: Two in-person meetings (held in September 2011 in Washington, DC, USA, and in February 2012 in Rotterdam, The Netherlands) involving VARC study group members, independent experts (including surgeons, interventional and non-interventional cardiologists, imaging specialists, neurologists, geriatric specialists, and clinical trialists), the United States Food and Drug Administration (FDA), and industry representatives, provided much of the substantive discussion from which this VARC-2 consensus manuscript was derived. This document also provides an overview of risk assessment and patient stratification that needed to be considered for accurate patient inclusion in studies. Working groups were assigned to define the following clinical endpoints: mortality, stroke, myocardial infarction, bleeding, acute kidney injury, vascular complications, conduction disturbances & arrhythmias, and a miscellaneous category including relevant complications not previously categorized. Furthermore, comprehensive echocardiographic recommendations are provided for evaluation of prosthetic valve (dys)function. Definitions for quality of life assessments are also reporte

Published
2012
Full Text
View/download PDF

40. 319 Body Mass Index And Waist Circumference Are Strong Predictors of High On-Treatement Platelet Reactivity in Patients Treated With Clopidogrel

Author

Ong, G., primary, Roy, M., additional, Déry, U., additional, Rinfret, S., additional, Bertrand, O.F., additional, Rodés-Cabau, J., additional, Barbeau, G., additional, Proulx, G., additional, Noël, B., additional, Larose, E., additional, Roy, L., additional, Gleeton, O., additional, Nguyen, C.M., additional, DeLarochellière, R., additional, Després, J.P., additional, Poirier, P., additional, and Déry, J.P., additional

Published
2012
Full Text
View/download PDF

41. 166 Correlation Between Cytochrome P450 2C19 Enzymatic Activity Assessed by [13C]-Pantoprazole Breath Test and Platelet Reactivity in Patients Treated With Clopidogrel After Percutaneous Coronary Intervention

Author

Harvey, A., primary, Déry, U., additional, Roy, M., additional, Modak, A., additional, Rinfret, S., additional, Bertrand, O.F., additional, Larose, E., additional, Rodés-Cabau, J., additional, Barbeau, G., additional, Gleeton, O., additional, Nguyen, C.M., additional, Proulx, G., additional, Noël, B., additional, Roy, L., additional, DeLarochellière, R., additional, and Déry, J.P., additional

Published
2012
Full Text
View/download PDF

42. 273 Bivalirudin Versus Heparin-Monotherapy in All Comers After Percutaneous Intervention: The Québec Heart-Lung Institute Experience

Author

MacHaalany, J., primary, Abdelaal, E., additional, Bataille, Y., additional, Larose, É., additional, Déry, J., additional, Delarochellière, R., additional, Rinfret, S., additional, Roy, L., additional, Proulx, G., additional, Gleeton, O., additional, Rodés-Cabau, J., additional, Noël, B., additional, Barbeau, G., additional, Nguyen, C., additional, Costerousse, O., additional, and Bertrand, O.F., additional

Published
2012
Full Text
View/download PDF

43. 168 Interaction Between 2C19*2 Gene Polymorphism and Proton Pump Inhibitors on Platelet Reactivity in Clopidogrel-Treated Patients

Author

Nadeau, P., primary, Déry, U., additional, Roy, M., additional, Bertrand, O.F., additional, Rodés-Cabau, J., additional, Larose, É., additional, Rinfret, S., additional, Noël, B., additional, Gleeton, O., additional, Roy, L., additional, Proulx, G., additional, Nguyen, C.M., additional, Barbeau, G., additional, DeLarochellière, R., additional, and Déry, J.P., additional

Published
2012
Full Text
View/download PDF

45. 295 Incidence and Predictors of Radial Failure in Patients Undergoing PCI At Québec Heart-Lung Institute, A Tertiary Care High-Volume Radial Centre

Author

Abdelaal, E., primary, Brousseau-Provencher, C., additional, MacHaalany, J., additional, Bataille, Y., additional, Déry, J., additional, Larose, É., additional, De Larochellière, R., additional, Rinfret, S., additional, Roy, L., additional, Proulx, G., additional, Gleeton, O., additional, Rodés-Cabau, J., additional, Noël, B., additional, Barbeau, G., additional, Nguyen, C.M., additional, Costerousse, O., additional, and Bertrand, O.F., additional

Published
2012
Full Text
View/download PDF

48. 336 PON1-Q192R polymorphism has no effect on platelet reactivity in patients treated with clopidogrel

Author

Déry, U., primary, Roy, M., additional, Khalil, A., additional, Nadeau, P.L., additional, Giguère, M.E., additional, Rodés-Cabau, J., additional, Larose, E., additional, Rinfret, S., additional, Gleeton, O., additional, Proulx, G., additional, Barbeau, G., additional, Noël, B., additional, Roy, L., additional, De Larochellière, R., additional, Nguyen, C.M., additional, Bossé, Y., additional, Tricoci, P., additional, Becker, R.C., additional, Bertrand, O.F., additional, and Déry, J.P., additional

Published
2011
Full Text
View/download PDF

50. 239 Predicting high on-treatment platelet reactivity in patients with acute coronary syndromes: Role of body mass index and waist circumference

Author

Roy, M., primary, Déry, U., additional, Lachance, P., additional, Bertrand, O.F., additional, Larose, E., additional, Rinfret, S., additional, Gleeton, O., additional, Proulx, G., additional, Barbeau, G., additional, Noël, B., additional, Roy, L., additional, De Larochellière, R., additional, Nguyen, C.M., additional, Rodés-Cabau, J., additional, Poirier, P., additional, Després, J.P., additional, and Déry, J.P., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results